Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05820893 · ClinicalTrials.gov registry record · Phase 2
Resistant Potato Starch to Alleviate GWI
A Phase 2 study of Gulf War Illness, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT05820893: Recruiting Phase 2 study of Gulf War Illness, sponsored by VA Office of Research and Development.
NCT05820893 is a Phase 2 study of Gulf War Illness that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 52 participants, below the 126-participant average among 14 other Gulf War Illness trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05820893, a Phase 2 study of Gulf War Illness, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
Gulf War Illness (GWI) affects an estimated 25-32% of the over 700,000 coalition troops deployed to the Persian Gulf as part of the First Gulf War. GWI causes a range of pain, fatigue, gastrointestinal, skin, neurologic, and respiratory symptoms. New treatments to reduce GWI-associated morbidity are critically needed. Research suggests a role for the gastrointestinal microbiome in mediating health, including through impacting metabolism and immunity. The disruption of this microbiome plays a role in multiple diseases, and preliminary data suggest that Veterans with GWI have altered gut microbiota. The investigators will evaluate the effectiveness of a dietary fiber prebiotic supplement intervention on improving the quality of life of Veterans with GWI.
Primary Outcome
The gut microbiome will be assessed using next generation sequencing (shotgun metagenomics)
Conditions Studied
Interventions
- DRUG Resistant Potato Starch
Study Locations (1)
Wisconsin
- William S. Middleton Memorial Veterans Hospital, Madison, WI - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2025-02-03 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 2 |
What NCT05820893 shows while recruiting
NCT05820893 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 126-participant average among 14 other Gulf War Illness trials with a reported enrollment target (59% lower).
The record links to 1 condition, with Gulf War Illness appearing as the primary indexed condition, and to 1 intervention - of which Resistant Potato Starch is the first listed.
NCT05820893 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT05820893 about?
NCT05820893 is a clinical study titled "Resistant Potato Starch to Alleviate GWI". Gulf War Illness (GWI) affects an estimated 25-32% of the over 700,000 coalition troops deployed to the Persian Gulf as part of the First Gulf War. GWI causes a range of pain, fatigue, gastrointestinal, skin, neurologic, and respiratory symptoms. New treatments to reduce GWI-associated morbidity are...
What is the current status of trial NCT05820893?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2025-02-03. Estimated completion is 2028-06-30.
What conditions does trial NCT05820893 study?
This clinical trial studies the following conditions: Gulf War Illness.
What interventions are being tested in trial NCT05820893?
The interventions under investigation include: Resistant Potato Starch (DRUG).
Who is sponsoring clinical trial NCT05820893?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05820893 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gulf War Illness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05820893's enrollment target sits among peer trials
52 12th of 14 higher than 2 of 14 other Gulf War Illness trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gulf War Illness trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ca-Mg Butyrate in GWI
RECRUITING · Phase 2
-
Study of Bacopa in Gulf War Illness Patients
RECRUITING · Phase 2
-
Confirmation of Diet as a Treatment for Gulf War Illness
RECRUITING · Phase 3
-
NIH Investigative Deep Phenotyping Study of Gulf War Veteran Health (Project NIH IN-DEPTH)
RECRUITING
-
Validating Gulf War Illness Blood Biomarkers
RECRUITING
-
Nicotinamide Riboside Clinical Trial for GWI
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI